Strata Skin Sciences (FRA:E2O) Cyclically Adjusted Revenue per Share: €129.24 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:E2O Strata Skin Sciences Inc FRA:E2O
38 GF Score
Price €3.76
GF Value €1,526.56
! 4 Warning Signs
View Full Analysis

What is Strata Skin Sciences Cyclically Adjusted Revenue per Share?

Strata Skin Sciences FRA:E2O 38 Cyclically Adjusted Revenue per Share is €129.24 as of Dec. 2025. GuruFocus rates FRA:E2O with a GF Score™ of 38/100 and a GF Value™ of €1,526.56. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Strata Skin Sciences's adjusted revenue per share for the three months ended in Dec. 2025 was €1.506. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €129.24 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Strata Skin Sciences's average Cyclically Adjusted Revenue Growth Rate was -20.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -5.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -0.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Strata Skin Sciences was 112.40% per year. The lowest was -7.80% per year. And the median was 2.90% per year.

As of today (2026-07-29), Strata Skin Sciences's current stock price is €3.76. Strata Skin Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was €129.24. Strata Skin Sciences's Cyclically Adjusted PS Ratio of today is 0.03.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Strata Skin Sciences was 0.92. The lowest was 0.01. And the median was 0.25.


Strata Skin Sciences  (FRA:E2O) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Strata Skin Sciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.76/129.24
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Strata Skin Sciences was 0.92. The lowest was 0.01. And the median was 0.25.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Strata Skin Sciences Cyclically Adjusted Revenue per Share Related Terms


Strata Skin Sciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Strata Skin Sciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strata Skin Sciences Cyclically Adjusted Revenue per Share Chart

Strata Skin Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.51 47.75 46.86 69.92 129.24

Strata Skin Sciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.92 78.19 90.54 90.64 129.24

FRA:E2O vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Strata Skin Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strata Skin Sciences Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Strata Skin Sciences's Cyclically Adjusted PS Ratio falls into.


FRA:E2O
38GF Score
Strata Skin Sciences Inc FRA:E2O
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Strata Skin Sciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Strata Skin Sciences's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=1.506/324.0540*324.0540
=1.506

Current CPI (Dec. 2025) = 324.0540.

Strata Skin Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 25.726 238.132 35.008
201606 29.818 241.018 40.091
201609 32.336 241.428 43.403
201612 26.717 241.432 35.860
201703 30.440 243.801 40.460
201706 32.356 244.955 42.804
201709 24.645 246.819 32.357
201712 19.457 246.524 25.576
201803 12.392 249.554 16.091
201806 4.606 251.989 5.923
201809 2.214 252.439 2.842
201812 2.348 251.233 3.029
201903 2.157 254.202 2.750
201906 2.180 256.143 2.758
201909 2.064 256.759 2.605
201912 2.433 256.974 3.068
202003 1.837 258.115 2.306
202006 1.061 257.797 1.334
202009 1.412 260.280 1.758
202012 1.634 260.474 2.033
202103 1.448 264.877 1.772
202106 1.785 271.696 2.129
202109 1.919 274.310 2.267
202112 2.332 278.802 2.711
202203 1.843 287.504 2.077
202206 2.481 296.311 2.713
202209 2.738 296.808 2.989
202212 2.882 296.797 3.147
202303 2.028 301.836 2.177
202306 2.183 305.109 2.319
202309 2.376 307.789 2.502
202312 2.275 306.746 2.403
202403 1.772 312.332 1.839
202406 2.235 314.175 2.305
202409 1.962 315.301 2.016
202412 2.191 315.605 2.250
202503 1.511 319.799 1.531
202506 1.593 322.561 1.600
202509 1.318 324.800 1.315
202512 1.506 324.054 1.506

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €129.24 mean?
Strata Skin Sciences (FRA:E2O) has a Cyclically Adjusted Revenue per Share of €129.24 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Strata Skin Sciences and its competitors.
Is Strata Skin Sciences' Cyclically Adjusted Revenue per Share too high?
Strata Skin Sciences' current Cyclically Adjusted Revenue per Share is €129.24. Overall, Strata Skin Sciences has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Strata Skin Sciences' Cyclically Adjusted Revenue per Share compare to ABT and SYK?
Strata Skin Sciences' Cyclically Adjusted Revenue per Share of €129.24 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Strata Skin Sciences and its competitors. Strata Skin Sciences's current Cyclically Adjusted Revenue per Share is €129.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Skin Sciences stock overvalued right now?
Strata Skin Sciences (FRA:E2O) has a current Cyclically Adjusted Revenue per Share of €129.24. The stock's GF Value™ is €1,526.56, compared to a current price of €3.76 — trading 99.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €129.24. Strata Skin Sciences' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Strata Skin Sciences (FRA:E2O), the current Cyclically Adjusted Revenue per Share is €129.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strata Skin Sciences (FRA:E2O) Overvalued in 2026?

Based on GuruFocus' analysis, Strata Skin Sciences stock appears to be undervalued. The current stock price of €3.76 is trading 99.8% below its estimated GF Value™ of €1,526.56.

Key valuation signals for FRA:E2O:

  • Cyclically Adjusted Revenue per Share: €129.24
  • GF Value™: €1,526.56 vs. price of €3.76 (99.8% below fair value)
  • GF Score™: 38/100 with 4 warning signs

No single metric tells the full story. See the FRA:E2O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Strata Skin Sciences Business Description

Other Exchanges SSKN:USA
Address 5 Walnut Grove Drive, Suite 140, Horsham, PA, USA, 19044
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
38GF Score

Get the complete analysis for FRA:E2O

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.76
Price
€1,526.56
GF Value